Skip to main content

Company News

Clinical research courses

  • Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets

    Zydus Cadila has received tentative approval from the USFDA to market Ibrutinib Tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg. Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

  • Junshi Biosciences and Immorna collaborate to develop mRNA therapeutics and vaccines

    Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA te

  • Recruitment for Phase 2 Trial of Lyme Disease Vaccine completed by Pfizer

    Valneva SE a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.

  • Torrent Pharmaceutical gets exemption of DPCO for their formulation Tapentadol Nasal Spray

    National Pharmaceutical Pricing Authority (NPPA) grants exemption from Drugs Price Control Order (DPCO) 2013 to Torrent Pharmaceuticals for their formulation of Tapentadol Nasal Spray.

  • Sun Pharma Announces Settlement of Patent Litigation for Generic Revlimid (lenalidomide) in US

    Sun Pharmaceutical Industries Limited along with one of its wholly owned subsidiaries announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid® (lenalidomide capsules) in the US.

  • Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets

    Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

  • One-dose Janssen COVID-19 vaccine approved by the MHRA

    The COVID-19 Vaccine Janssen has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency . This is the fourth COVID-19 vaccine to be authorised by the UKs independent regulator and is the first to be approved for protection against COVID-19 with a single dose.

  • Bal Pharma Ltd launch of Favipiravir formulation into Indian market, under the brand name BALflu

    Bal Pharma Ltd is pleased to announce the launch of Favipiravir formulation into Indian market, under the brand name BALflu.

  • Roche Tecentriq helps certain people with early lung cancer live

    Roche announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC.

  • Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY

    Pfizer Inc. announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY, the companies COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.

Subscribe to Company News